크레아틴 키나아제-MB 시장 : 세계 예측(2026-2032년)

The Creatine Kinase MB Market is projected to grow by USD 2.27 billion at a CAGR of 7.20% by 2032.

Creatine Kinase-MB: Clinical Role and Executive Context

Creatine kinase-MB (CK-MB) is an isoenzyme historically used to support assessment of myocardial injury. It is released when cardiac and skeletal muscle cells are damaged, but its diagnostic specificity is limited because skeletal muscle injury, surgery, inflammation, and renal dysfunction can also elevate concentrations. In contemporary practice, CK-MB is generally interpreted alongside symptoms, electrocardiography, imaging, serial biomarker results, and clinical history rather than used as a standalone determinant of acute myocardial infarction.

High-sensitivity cardiac troponin is now the preferred biomarker in major international clinical guidelines because it offers greater cardiac specificity and supports earlier detection of myocardial injury. CK-MB nevertheless retains relevance in selected settings, including some institutions with established testing workflows, evaluation of reinfarction when a falling marker may be informative, and circumstances in which troponin interpretation is complicated by analytical or clinical factors.

Diagnostic Practice Is Shifting Toward High-Sensitivity, Integrated Pathways

The principal transformation is the movement from isolated enzyme testing toward protocolized, serial assessment of myocardial injury. Emergency departments increasingly combine risk stratification, electrocardiography, imaging, and high-sensitivity troponin algorithms to shorten decision times while reducing unnecessary admissions and repeat testing. This change has narrowed the routine role of CK-MB, particularly where laboratory and clinical systems are aligned with current cardiology guidance.

At the same time, diagnostic stewardship is becoming more important. Laboratories and hospitals are reviewing test menus, reflex rules, reference intervals, turnaround requirements, and clinician education to prevent discordant or low-value testing. CK-MB can remain useful when its result is interpreted within a defined clinical pathway, but indiscriminate ordering may increase false-positive findings and complicate care.

Artificial Intelligence Can Improve Triage, Interpretation, and Laboratory Operations

Artificial intelligence is contributing to cardiovascular diagnostics through risk prediction, electrocardiogram interpretation, image analysis, workflow prioritization, and extraction of structured information from clinical records. These tools may help identify patients requiring urgent evaluation, recognize subtle patterns associated with myocardial injury, and support more consistent integration of symptoms, electrocardiography, biomarkers, and comorbidities.

For CK-MB specifically, AI is more likely to influence ordering and interpretation than replace the assay itself. Models can flag discordance between CK-MB and troponin, identify repeat-testing patterns, and support laboratory utilization management. Safe adoption requires representative validation, transparent performance assessment, protection against data drift, human oversight, and monitoring for unequal outcomes across demographic and clinical subgroups.

Regional Insights: Uneven Adoption of Contemporary Cardiac Biomarker Pathways

North America and Europe generally have broad access to high-sensitivity troponin, accredited laboratories, and established acute coronary syndrome pathways, although practice variation persists across hospitals. Asia-Pacific combines advanced urban diagnostic infrastructure with substantial differences in access, reimbursement, and laboratory capacity between metropolitan and rural settings. These conditions can preserve a role for CK-MB where newer platforms are unavailable or implementation is incomplete.

Latin America, the Middle East, and Africa show similarly diverse adoption patterns. Referral networks, procurement constraints, workforce availability, and emergency-care capacity influence whether clinicians can apply serial biomarker algorithms consistently. Regional priorities therefore include reliable supply, quality assurance, locally appropriate reference intervals, clinician training, and diagnostic pathways that reflect the resources available without compromising clinical safety.

Group Insights: Policy, Trade, and Security Networks Shape Diagnostic Readiness

ASEAN's varied health-system maturity makes interoperability, workforce development, and affordable access important considerations for cardiac biomarker testing. BRICS members encompass major differences in laboratory infrastructure, domestic manufacturing capacity, reimbursement, and clinical practice, making country-level implementation more informative than a single group-wide assumption.

The European Union benefits from shared regulatory and clinical-policy structures, while the G7 generally combines advanced laboratory capability with active evaluation of diagnostic stewardship and digital health. GCC states often possess well-resourced tertiary-care facilities but may still face differences between centralized specialist centers and distributed services. NATO countries span diverse health systems; their common emphasis on resilience, preparedness, and interoperability highlights the value of secure laboratory supply chains and dependable emergency diagnostics.

Country Insights: Distinct Clinical and Infrastructure Priorities

Australia, Canada, the United Kingdom, the United States, France, Germany, Italy, Spain, and Japan generally operate within mature cardiovascular-care systems where high-sensitivity troponin-centered pathways have reduced routine dependence on CK-MB. Their priorities include harmonized protocols, appropriate use criteria, analytical comparability, and integration with digital emergency-care systems. South Korea likewise combines advanced diagnostic infrastructure with strong interest in technology-enabled clinical workflows.

China and India contain substantial variation across urban tertiary hospitals, community facilities, and rural services. Expanding access to reliable cardiac testing, strengthening quality systems, and improving referral coordination are important implementation themes. Brazil, Mexico, and Russia also show differences by region and institution in laboratory access, procurement, and clinical adoption. Across all listed countries, CK-MB is most defensible when used selectively and interpreted with contemporary clinical evidence rather than as an automatic substitute for cardiac troponin.

Action Agenda: Align Testing, Technology, and Clinical Governance

Industry leaders should first position CK-MB within explicit diagnostic algorithms that define when it adds value, when troponin is preferred, and how discordant results should be handled. They should pair assay performance with clinician education, clear reporting language, validated reference intervals, and ongoing review of repeat-testing and false-positive patterns.

Second, organizations should invest in interoperable laboratory and clinical data systems, including decision support that surfaces serial trends and relevant confounders. AI initiatives should begin with narrowly defined, clinically supervised use cases and undergo prospective validation. Finally, leaders should strengthen quality management, continuity of reagents and instruments, cybersecurity, equitable access, and cross-border evidence sharing so that modernization improves outcomes without creating avoidable diagnostic gaps.

Research Methodology: Evidence-Led Synthesis of Clinical and System-Level Factors

This executive summary applies a qualitative evidence-synthesis approach centered on established cardiology guidance, laboratory medicine principles, peer-reviewed clinical evidence, and documented health-system practices. The assessment distinguishes CK-MB's analytical and clinical characteristics from broader cardiovascular diagnostic trends and considers how regulation, infrastructure, reimbursement, workforce capability, and digital transformation affect implementation.

Regional, group, and country observations are framed as comparative system-level insights rather than quantitative rankings. No market estimates, market shares, forecasts, or company-specific claims are used. Interpretations should be updated as clinical guidelines, assay technologies, regulatory requirements, and local care pathways evolve.

Conclusion: CK-MB Remains Selective Within a Troponin-Led Diagnostic Environment

CK-MB has an established history in evaluating myocardial injury, but contemporary evidence and guidelines place high-sensitivity cardiac troponin at the center of acute coronary syndrome assessment. The continuing value of CK-MB depends on disciplined, context-specific use rather than routine ordering.

The strongest path forward is integrated diagnostic governance: clinically justified testing, serial interpretation, robust laboratory quality, interoperable data, and carefully validated AI support. Regional and national differences make adaptable implementation essential, while consistent attention to patient safety and diagnostic stewardship should guide decisions across all health-system settings.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Creatine Kinase MB Market, by Product Type

• 7.1. Introduction
• 7.2. Instruments
  • 7.2.1. Bench Top Analyzers
  • 7.2.2. Point Of Care Analyzers
• 7.3. Kits And Reagents
  • 7.3.1. Lab Based Kits And Reagents
  • 7.3.2. Point Of Care Kits And Reagents

8. Creatine Kinase MB Market, by Technology

• 8.1. Introduction
• 8.2. Electrophoretic Assay
• 8.3. Immunoinhibition Assay
• 8.4. Mass Assay

9. Creatine Kinase MB Market, by End User

• 9.1. Introduction
• 9.2. Academic And Research Institutes
• 9.3. Diagnostic Laboratories
• 9.4. Hospitals

10. Creatine Kinase MB Market, by Application

• 10.1. Introduction
• 10.2. Early Diagnosis Of Myocardial Infarction
• 10.3. Monitoring Of Myocardial Injury
• 10.4. Risk Stratification

11. Creatine Kinase MB Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Direct Tender
• 11.3. Hospital Pharmacies
• 11.4. Online Sales
• 11.5. Retail Pharmacies

12. Creatine Kinase MB Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. Creatine Kinase MB Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. Creatine Kinase MB Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Becton, Dickinson and Company
• 16.3. Bio-Rad Laboratories, Inc.
• 16.4. bioMerieux SA
• 16.5. Danaher Corporation
• 16.6. DiaSorin S.p.A.
• 16.7. F. Hoffmann-La Roche AG
• 16.8. Guangzhou Wondfo Biotech Co., Ltd.
• 16.9. LSI Medience Corporation
• 16.10. PerkinElmer, Inc. (Revvity)
• 16.11. QuidelOrtho
• 16.12. Randox Laboratories
• 16.13. Siemens Healthineers AG
• 16.14. Thermo Fisher Scientific Inc.
• 16.15. Tosoh Corporation

17. Key Experts